

Level 14, Cigna House,  
40 Mercer Street, PO Box 10-254  
Wellington 6001, New Zealand  
Phone 64 4 460 4990  
Fax 64 4 460 4995  
www.pharmac.govt.nz

15 October 2003

**To: All Pharmaceutical Suppliers, Medical Groups and Interested Parties**

**CONSULTATION ON THE MDS DIAGNOSTICS LIMITED PROPOSAL INVOLVING THE LISTING OF MARQUIS CONDOMS AND REFERENCE PRICING OF CONDOMS**

PHARMAC and MDS Diagnostics Ltd have signed a provisional agreement relating to the listing of Marquis Condoms on the Pharmaceutical Schedule. Acceptance of this provisional agreement is subject to consultation and PHARMAC Board or Chief Executive approval.

The PHARMAC Chief Executive will consider this proposal under Delegated Authority in October 2003. If you have comments to make on this proposal and would like those comments to be considered by the PHARMAC Chief Executive then please send them to Natalie Ganley at PHARMAC **by 5 p.m. on Friday, 13 November 2003**. The Chief Executive will consider all comments submitted by this date.

The main features of this proposal are as follows:

- PHARMAC would list on the Pharmaceutical Schedule, with effect from 1 January 2004, Marquis Condoms Non-spermicidal and Marquis Condoms Extra-strength at a price and subsidy of \$14.84 per 144 and \$16.21 per 144 (ex-manufacturer, exc. GST) respectively.
- PHARMAC would reference price all other brands of Non-spermicidal and Extra-strength condoms listed on the Pharmaceutical Schedule, with effect from 1 January 2004, to the new subsidy of \$14.84 per 144 and \$16.21 per 144 (ex-manufacturer, exc. GST) respectively.

If you wish to make comments on this proposal, please forward them to PHARMAC by **5pm, on Friday, 13 November 2003**.

Yours sincerely



Natalie Ganley  
Therapeutic Group Manager